Literature DB >> 3155882

Ly-1+2- suppressor T cells inhibit the expression of passively transferred antitumor immunity by suppressing the generation of cytolytic T cells.

C D Mills, R J North.   

Abstract

The results of this study confirm and extend previous findings from this laboratory by showing that the suppressor T cells that are generated during progressive growth of the P815 tumor and inhibit the antitumor cytolytic response in adoptively immunized T-cell-deficient recipients are of the Ly-1+2- phenotype. Thus, Ly-2+ cytolytic effector T cells and suppressor T cells in the system can be distinguished by the complete resistance of suppressor T cells to elimination by anti-Ly-2-antibody-plus-complement treatment. The suppressor cells in this system are different, therefore, from those in most other systems in which suppressor cells, like cytolytic T cells, are Ly2+ or the equivalent rat or human phenotype. The present results also more clearly define how suppressor T cells inhibit the expression of antitumor immunity by showing that passively transferred suppressor T cells inhibit the production of cytolytic T cells in adoptively immunized T-cell-deficient recipients, but not the antitumor function of cytolytic T cells already generated. Finally, the results show that the expression of passively transferred antitumor immunity in T-cell-deficient recipients requires the participation of noncytolytic Ly-1+2- donor T cells. It is apparent, however, that T cells of this phenotype have no direct antitumor activity but function, instead, to "help" in the generation of cytolytic T cells in the recipient.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3155882     DOI: 10.1097/00007890-198502000-00018

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  6 in total

1.  Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors.

Authors:  A L Rakhmilevich; J Turner; M J Ford; D McCabe; W H Sun; P M Sondel; K Grota; N S Yang
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

2.  An extract of seeds from Aeginetia indica L., a parasitic plant, induces potent antigen-specific antitumor immunity in Meth A-bearing BALB/c mice.

Authors:  J G Chai; T Bando; S Kobashi; M Oka; H Nagasawa; S Nakai; K Maeda; K Himeno; M Sato; S Ohkubo
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

3.  Tumour-associated proliferative responses in vitro of regional lymph nodes draining solid cancers in man.

Authors:  T Mainou-Fowler; O Eremin
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

4.  Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden.

Authors:  M Awwad; R J North
Journal:  Immunology       Date:  1988-09       Impact factor: 7.397

Review 5.  Defining Immunogenic and Radioimmunogenic Tumors.

Authors:  Terry R Medler; Tiffany C Blair; Marka R Crittenden; Michael J Gough
Journal:  Front Oncol       Date:  2021-03-19       Impact factor: 6.244

Review 6.  Development and therapeutic manipulation of the head and neck cancer tumor environment to improve clinical outcomes.

Authors:  Thomas Duhen; Michael J Gough; Rom S Leidner; Sasha E Stanton
Journal:  Front Oral Health       Date:  2022-07-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.